Berlin, Germany, and Cluj-Napoca, Romania – October 2025 – StratifAI, the AI biomarker company for precision oncology, has announced a partnership with the Prof. Dr. Ion Chiricuță Oncology Institute (IOCN), a leading cancer care and research center in Romania. Through this collaboration, StratifAI gains exclusive access to IOCN’s extensive clinical data and expertise to validate the first product built on its Polaris™ platform, an AI-based breast cancer recurrence risk test, while also expanding analyses to ovarian cancer as part of broader platform validation.
Advancing risk stratification through AI
The validation aims to demonstrate the ability of Polaris™ Breast to predict breast cancer recurrence using routinely collected pathology slides and clinical data. Built on a foundation model that analyzes routinely available histology slides in combination with standard clinicopathological variables, Polaris™ is designed to deliver rapid, accurate, and cost-effective alternatives to genomic assays in real-world clinical practice.
The partnership will combine insights from both past and present clinical experience. Retrospectively, StratifAI will analyze real-world data from previously treated breast cancer patients, using existing clinical records and pathology slides to measure the model’s prognostic performance with respect to actual patient outcomes. Prospectively, the tool will be evaluated in newly diagnosed patients within an observational study, allowing its performance and practicality to be assessed directly in routine oncology practice.
Enabling scalable cancer diagnostics
The Prof. Dr. Ion Chiricuță Oncology Institute, with decades of oncology expertise and access to one of Eastern Europe’s largest cancer patient datasets, provides the clinical foundation to validate StratifAI Polaris™ in real-world settings. Together, StratifAI and IOCN are ensuring that AI-powered biomarkers are not only scientifically rigorous but also practical for routine use. By integrating seamlessly into existing clinical workflows, Polaris™ is designed to help clinicians make more confident decisions while enabling healthcare systems to scale access to precision oncology for patients worldwide.
